The Toronto Postliver Transplantation Hepatocellular Carcinoma Recurrence Calculator: A Machine Learning Approach

Tommy Ivanics, Walter Nelson, Madhukar S. Patel, Marco P.A.W. Claasen, Lawrence Lau, Andre Gorgen, Phillipe Abreu, Anna Goldenberg, Lauren Erdman, Gonzalo Sapisochin – 8 October 2021 – Liver transplantation (LT) listing criteria for hepatocellular carcinoma (HCC) remain controversial. To optimize the utility of limited donor organs, this study aims to leverage machine learning to develop an accurate posttransplantation HCC recurrence prediction calculator. Patients with HCC listed for LT from 2000 to 2016 were identified, with 739 patients who underwent LT used for modeling.

A Meta‐Analysis and Systematic Review on the Global Prevalence, Risk Factors, and Outcomes of Coronary Artery Disease in Liver Transplantation Recipients

Jieling Xiao, Jie Ning Yong, Cheng Han Ng, Nicholas Syn, Wen Hui Lim, Darren Jun Hao Tan, En Ying Tan, Daniel Huang, Raymond C. Wong, Nicholas W. S. Chew, Eunice Xiang Xuan Tan, Mazen Noureddin, Mohammad Shadab Siddiqui, Mark D. Muthiah – 7 October 2021 – The shift in the changing etiology of cirrhosis requiring liver transplantation (LT) has resulted in an increasing prevalence of coronary artery disease (CAD) that can potentially impact post‐LT outcomes.

Turning the Tide on Hepatitis C Virus–Related Liver Transplantation: The Return on Investment in Hepatitis C Virus Treatment in Australia and New Zealand

Jess Howell, Avik Majumdar, Michael A. Fink, Mandy Byrne, Geoff McCaughan, Simone I. Strasser, Michael Crawford, Peter Hodgkinson, Katherine A. Stuart, Caroline Tallis, John Chen, Alan Wigg, Robert Jones, Bryon Jaques, Gary Jeffrey, Leon Adams, Michael C. Wallace, Stephen Munn, Ed Gane, Alex J.

Macrophage nuclear factor erythroid 2‐related factor 2 deficiency promotes innate immune activation by tissue inhibitor of metalloproteinase 3–mediated RhoA/ROCK pathway in the ischemic liver

Subscribe to